中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2013年
15期
23-25
,共3页
脑血管意外%抑郁%艾司西酞普兰%醒脑静
腦血管意外%抑鬱%艾司西酞普蘭%醒腦靜
뇌혈관의외%억욱%애사서태보란%성뇌정
Cerebrovascular accident%Depression%Escitalopram%Xingnaojing
目的 探讨艾司西酞普兰(ESC)联合醒脑静治疗脑卒中后抑郁的临床疗效.方法 将74例脑卒中后抑郁患者按随机数字表法分为治疗组(38例,给予ESC联合醒脑静治疗)和对照组(36例,给予ESC治疗).比较两组患者汉密尔顿抑郁量表(HAMD)、简易精神状态检查(MMSE)、记忆商(MQ)及日常生活活动能力(ADL)评分,临床疗效,不良反应.结果 对照组和治疗组治疗后HAMD、MMSE、MQ、ADL评分均较治疗前显著改善[对照组:(14.26±2.61)分比(29.73±5.17)分、(23.26±3.75)分比(21.24±3.38)分、(86.53±6.49)分比(82.35±5.42)分、(61.37±3.72)分比(45.32±4.48)分,治疗组:(10.31±2.08)分比(29.57±6.09)分、(27.83±4.31)分比(21.63±3.82)分、(95.63±6.41)分比(82.30±7.48)分、(69.15±6.39)分比(45.27±4.28)分],差异有统计学意义(P＜0.05)；且治疗组治疗后均显著优于对照组,差异有统计学意义(P＜0.05).治疗组总有效率显著高于对照组[97.4％(37/38)比86.1％(31/36)],差异有统计学意义(P＜0.05).两组不良反应发生率比较差异无统计学意义(P＞0.05).结论 ESC联合醒脑静治疗脑卒中后抑郁,疗效确切,安全性好,值得临床进一步应用推广.
目的 探討艾司西酞普蘭(ESC)聯閤醒腦靜治療腦卒中後抑鬱的臨床療效.方法 將74例腦卒中後抑鬱患者按隨機數字錶法分為治療組(38例,給予ESC聯閤醒腦靜治療)和對照組(36例,給予ESC治療).比較兩組患者漢密爾頓抑鬱量錶(HAMD)、簡易精神狀態檢查(MMSE)、記憶商(MQ)及日常生活活動能力(ADL)評分,臨床療效,不良反應.結果 對照組和治療組治療後HAMD、MMSE、MQ、ADL評分均較治療前顯著改善[對照組:(14.26±2.61)分比(29.73±5.17)分、(23.26±3.75)分比(21.24±3.38)分、(86.53±6.49)分比(82.35±5.42)分、(61.37±3.72)分比(45.32±4.48)分,治療組:(10.31±2.08)分比(29.57±6.09)分、(27.83±4.31)分比(21.63±3.82)分、(95.63±6.41)分比(82.30±7.48)分、(69.15±6.39)分比(45.27±4.28)分],差異有統計學意義(P＜0.05)；且治療組治療後均顯著優于對照組,差異有統計學意義(P＜0.05).治療組總有效率顯著高于對照組[97.4％(37/38)比86.1％(31/36)],差異有統計學意義(P＜0.05).兩組不良反應髮生率比較差異無統計學意義(P＞0.05).結論 ESC聯閤醒腦靜治療腦卒中後抑鬱,療效確切,安全性好,值得臨床進一步應用推廣.
목적 탐토애사서태보란(ESC)연합성뇌정치료뇌졸중후억욱적림상료효.방법 장74례뇌졸중후억욱환자안수궤수자표법분위치료조(38례,급여ESC연합성뇌정치료)화대조조(36례,급여ESC치료).비교량조환자한밀이돈억욱량표(HAMD)、간역정신상태검사(MMSE)、기억상(MQ)급일상생활활동능력(ADL)평분,림상료효,불량반응.결과 대조조화치료조치료후HAMD、MMSE、MQ、ADL평분균교치료전현저개선[대조조:(14.26±2.61)분비(29.73±5.17)분、(23.26±3.75)분비(21.24±3.38)분、(86.53±6.49)분비(82.35±5.42)분、(61.37±3.72)분비(45.32±4.48)분,치료조:(10.31±2.08)분비(29.57±6.09)분、(27.83±4.31)분비(21.63±3.82)분、(95.63±6.41)분비(82.30±7.48)분、(69.15±6.39)분비(45.27±4.28)분],차이유통계학의의(P＜0.05)；차치료조치료후균현저우우대조조,차이유통계학의의(P＜0.05).치료조총유효솔현저고우대조조[97.4％(37/38)비86.1％(31/36)],차이유통계학의의(P＜0.05).량조불량반응발생솔비교차이무통계학의의(P＞0.05).결론 ESC연합성뇌정치료뇌졸중후억욱,료효학절,안전성호,치득림상진일보응용추엄.
Objective To explore the clinical effect of escitalopram combined with xingnaojing in post-stroke depression (PSD).Methods Seventy-four cases with PSD were divided into treatment group (38 cases) and control group (36 cases) by random digits table,control group was given escitalopram,treatment group was given escitalopram and xingnaojing.Hamilton depression scale (HAMD),mental state examination (MMSE),memory quotient (MQ) and activities of daily life (ADL) score,clinical curative effect and adverse reaction were compared between 2 groups.Results The HAMD,MMSE,MQ,ADL score after treatment in 2 groups were significantly better than those before treatment [control group:(14.26 ± 2.61)scores vs.(29.73 ± 5.17) scores,(23.26 ± 3.75) scores vs.(21.24 ± 3.38) scores,(86.53 ± 6.49) scores vs.(82.35 ± 5.42) scores,(61.37 ± 3.72) scores vs.(45.32 ±4.48) scores;treatment group:(10.31 ± 2.08)scores vs.(29.57 ± 6.09) scores,(27.83 ± 4.31) scores vs.(21.63 ± 3.82) scores,(95.63 ± 6.41) scores vs.(82.30 ± 7.48) scores,(69.15 ± 6.39) scores vs.(45.27 ± 4.28) scores,P ＜ 0.05].The HAMD,MMSE,MQ,ADL score after treatment in treatment group were significantly better than those in control group (P ＜0.05).The total effective rate in treatment group was significantly higher than that in control group [97.4％(37/38) vs.86.1％(31/36),P ＜ 0.05].There was no significant difference in rate of adverse reaction between 2 groups (P＞ 0.05).Conclusion Escitalopram combined with xingnaojing in PSD is effective and safe,and worth further clinical application promotion.
